Cancers downregulate the expression of these miRNAs and/or reduce their systemic abundance via an unknown mechanism, leading to high baseline AKT activity and potentially resulting into accelerated cancer growth and drug resistance (Fig. 3r). Here, AKT1 is linked to cancer.